# A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

> **NCT00448292** · PHASE2 · COMPLETED · sponsor: **Epix Pharmaceuticals, Inc.** · enrollment: 330 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** PRX-00023
- **DRUG:** Placebo for PRX-00023

## Key facts

- **NCT ID:** NCT00448292
- **Lead sponsor:** Epix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2007-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448292, "A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00448292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*